検索結果

千寿製薬株式会社

or Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） September 4, 2025 Senju has develo...

mages on NAVIS-AZU or NAVIS-CL* by installing Logic and Design’s image sharpening algorithm. We aim to promote “more visibility” by providing products and services equipped with image sharpening and h...

mages on NAVIS-AZU or NAVIS-CL* by installing Logic and Design’s image sharpening algorithm. We aim to promote “more visibility” by providing products and services equipped with image sharpening and h...

お知らせ | 千寿製薬株式会社

or Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） September 4, 2025 Senju has develo...

Data And Statistics | About Senju | SENJU Pharmaceutical

e 40.7 40.8 46.4 48.9 48.9 Operating Profit 5.4 6.9 7.4 7.1 2.4 Ordinary Profit 8.0 9.1 8.7 9.1 2.9 Total Assets 75.8 83.9 88.2 98.4 100.2 ＊A new accounting standard for revenue recognition has been a...